Reading ATYR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ATYR free→Reading ATYR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ATYR free→QuarterlyIQ Insights · ATYR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per sha…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.